Skip to main content
Premium Trial:

Request an Annual Quote

MDVIP Physician Network to Offer Exact Sciences' ColoGuard

NEW YORK (GenomeWeb) – Exact Sciences today announced that physicians network MDVIP will make Exact's ColoGuard colorectal cancer screening test available to its affiliated nationwide network of more than 750 primary care physicians.

In a statement, MDVIP Chief Medical Officer Andrea Klemes said that adoption of ColoGuard "will allow our patients who are 50 years and older and at average risk for colorectal cancer an easy-to-use screening test which they can do in the privacy of their own home."

In August, Exact Sciences simultaneously received US Food and Drug Administration approval for Cologuard and a proposed National Coverage Determination from The Centers for Medicare & Medicaid Services.

The test is the first FDA-approved and Medicare-reimbursed non-invasive screening test for colorectal cancer that analyzes both stool-based DNA and blood biomarkers to detect cancer and precancer. CMS's final NCD this month deemed Cologuard to have sufficient evidence for coverage as a screening test for asymptomatic, average-risk beneficiaries aged 50 to 85 years, and set reimbursement at $502.

Prior to the finalized NCD, Exact Sciences announced that Group Health Cooperative would be the first health plan in Wisconsin to offer its patients Cologuard. In August, Mayo Clinic signed on as the first health system to adopt the test.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.